Vir Biotechnology, Inc. (VIR)
$10.83-$0.48 (-4.24%) Today
Janet Napolitano - Director
Vicki L. Sato - DirectorVicki L. Sato - DirectorVicki L. Sato - DirectorVicki L. Sato - DirectorVir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 3,579 | $34K |
| Grant or award | 4 | 48,000 | |
| Other acquisition / disposition | 2 | 16,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
61 Form 4 filings on record, the earliest from Oct 24, 2024, newest first. Filing history page 2 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 191,854 | $5.98 | $1.15M | |
| Vicki L. Sato - Director | Open-market sale | Common Stock | 22,000 | $6.00 | $132K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 127,938 | $6.39 | $818K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 61,493 | $6.44 | $396K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 227,803 | $6.15 | $1.40M | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 235,971 | $6.38 | $1.51M | |
| Jason O'Byrne - Officer | Open-market sale | Common Stock | 6,799 | $5.56 | $38K | |
| Verneuil Vanina de - Officer | Open-market sale | Common Stock | 2,385 | $5.16 | $12K | |
| Vicki L. Sato - Director | Open-market sale | Common Stock | 22,000 | $5.64 | $124K | |
| Verneuil Vanina de - Officer | Open-market sale | Common Stock | 1,365 | $5.86 | $8K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 24,453 | $6.50 | $159K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 100 | $6.49 | $649 | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 66,403 | $6.05 | $402K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 46,696 | $5.96 | $278K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 144,266 | $6.15 | $888K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 154,383 | $5.99 | $925K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 220,535 | $6.20 | $1.37M | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 109,675 | $6.30 | $691K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 16,671 | $6.07 | $101K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 12,844 | $6.10 | $78K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 249,060 | $6.14 | $1.53M | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 2,300 | $6.08 | $14K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 72,133 | $5.60 | $404K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 466,242 | $6.05 | $2.82M | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 450,342 | $5.56 | $2.50M | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 73,955 | $5.69 | $421K | |
| Vicki L. Sato - Director | Open-market sale | Common Stock | 22,000 | $5.84 | $128K | |
| Vicki L. Sato - Director | Open-market sale | Common Stock | 22,000 | $4.99 | $110K | |
| Vicki L. Sato - Director | Open-market sale | Common Stock | 22,000 | $4.99 | $110K | |
| Mark Eisner - Officer | Open-market sale | Common Stock | 6,796 | $5.47 | $37K | |
| Mark Eisner - Officer | Open-market sale | Common Stock | 3,586 | $5.47 | $20K | |
| Vicki L. Sato - Director | Open-market sale | Common Stock | 22,000 | $5.10 | $112K | |
| Robert J. More - Director | Other | Common Stock | 14,027 | $0.00 | - | |
| Robert J. More - Director | Other | Common Stock | 14,027 | $0.00 | - | |
| Norbert W. Bischofberger - Director | Other | Common Stock | 10,667 | $0.00 | - | |
| Norbert W. Bischofberger - Director | Other | Common Stock | 10,667 | $0.00 | - | |
| Norbert W. Bischofberger - Director | Grant or award | Common Stock | 8,000 | $0.00 | - | |
| Norbert W. Bischofberger - Director | Grant or award | Stock Option (Right to Buy) | 16,000 | $0.00 | - | |
| Robert J. More - Director | Grant or award | Common Stock | 8,000 | $0.00 | - | |
| Robert J. More - Director | Grant or award | Stock Option (Right to Buy) | 16,000 | $0.00 | - | |
| Vicki L. Sato - Director | Grant or award | Common Stock | 8,000 | $0.00 | - | |
| Vicki L. Sato - Director | Grant or award | Stock Option (Right to Buy) | 16,000 | $0.00 | - | |
| Verneuil Vanina de - Officer | Open-market sale | Common Stock | 76 | $8.22 | $625 | |
| Jason O'Byrne - Officer | Grant or award | Common Stock | 75,000 | $0.00 | - | |
| Jason O'Byrne - Officer | Grant or award | Stock Option (Right to Buy) | 150,000 | $0.00 | - | |
| Verneuil Vanina de - Officer | Open-market sale | Common Stock | 4,397 | $10.11 | $44K | |
| Verneuil Vanina de - Officer | Open-market sale | Common Stock | 1,403 | $7.20 | $10K | |
| Verneuil Vanina de - Officer | Open-market sale | Common Stock | 2,347 | $9.47 | $22K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| O'Byrne Jason | Former Officer | 23,148 | $243K | View on EDGAR | |
| O'Byrne Jason | Former Officer | 14,352 | $142K | View on EDGAR | |
| O'Byrne Jason | Former Officer | 25,000 | $245K | View on EDGAR |
Vir Biotechnology, Inc. (VIR) had 4 insider filings in the last 90 days, with the most recent on 2026-08-12. The full record for VIR runs to 61 Form 4 filings, the earliest from 2024-10-24. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of VIR were filed in the last 90 days.
2 insider sales of VIR were filed in the last 90 days, totaling $34K.
This page tracks VIR Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add VIR to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
